Skip to main content

Want a detailed portfolio tracker?

INDP
NASDAQ
$2.46

Indaptus Therapeutics Inc (INDP)

Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. Utilizing its proprietary platform, the company enhances the immune system's capacity to identify and eliminate tumor cells, thereby improving therapeutic efficacy and patient outcomes. With a robust pipeline of clinical candidates aimed at addressing critical unmet needs in oncology, Indaptus is strategically positioned for growth in a competitive market. By fostering collaborations with leading research institutions and a commitment to scientific innovation, Indaptus aspires to emerge as a key player in the biopharmaceutical sector.
Website: https://indaptusrx.com
Sector:
Healthcare
Industry:
Biotechnology
Target: $10 (+306.50%)

Market Cap

$319M

Free Cash Flow Yield

-5.26%

Beta (5Y)

1.56

Price Chart

Valuation
Market Cap$319M
P/B277.62
Profitability
EBITDA-$19M
EPS-$0.53
Financial Health
Free Cash Flow Yield-5.26%
Growth & Risk
Beta (5Y)1.56
Sharpe Ratio-0.05